within Pharmacolibrary.Drugs.ATC.A;

model A08AA11
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.697,
    Cl             = 0.35500000000000004,
    adminDuration  = 600,
    adminMass      = 0.01,
    adminCount     = 1,
    Vd             = 0.135,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006233333333333333,
    Tlag           = 9.96
  );

  annotation(Documentation(
    info ="<html><body><p>Lorcaserin is a selective serotonin 2C receptor agonist that was used as an anti-obesity agent to promote weight loss by decreasing appetite. It was approved for use in the United States but was withdrawn from the market in 2020 due to concerns over an increased risk of cancer.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects after oral administration, based on population PK modeling.</p><h4>References</h4><ol><li><p>Hurren, KM, &amp; Dunham, MW (2017). Pharmacokinetic drug evaluation of extended release lorcaserin for the treatment of obesity. <i>Expert opinion on drug metabolism &amp; toxicology</i> 13(8) 891–896. DOI:<a href=&quot;https://doi.org/10.1080/17425255.2017.1344214&quot;>10.1080/17425255.2017.1344214</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28636828/&quot;>https://pubmed.ncbi.nlm.nih.gov/28636828</a></p></li><li><p>Smith, BM, et al., &amp; Thomsen, WJ (2008). Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity. <i>Journal of medicinal chemistry</i> 51(2) 305–313. DOI:<a href=&quot;https://doi.org/10.1021/jm0709034&quot;>10.1021/jm0709034</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18095642/&quot;>https://pubmed.ncbi.nlm.nih.gov/18095642</a></p></li><li><p>Bajrai, AA, et al., &amp; Iqbal, M (2016). A Validated UPLC-MS-MS Assay for the Rapid Determination of Lorcaserin in Plasma and Brain Tissue Samples. <i>Journal of analytical toxicology</i> 40(2) 133–139. DOI:<a href=&quot;https://doi.org/10.1093/jat/bkv126&quot;>10.1093/jat/bkv126</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26567546/&quot;>https://pubmed.ncbi.nlm.nih.gov/26567546</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A08AA11;
